cxcr4 peptide antagonist a compound that inhibits the activity of the CXCR4 receptor - what-needle-for-peptides Peptide LY2510924 is a potent and selective CXCR4 antagonist CXCR4 Peptide Antagonists: Promising Agents in Cancer Therapy and Beyond

how-to-take-a-semaglutide-shot The CXCR4 peptide antagonist field is a dynamic area of research, primarily focused on developing novel therapeutic strategies for various diseases, most notably cancer. CXCR4, a chemokine receptor, plays a critical role in cell migration, proliferation, and survival. Its interaction with its ligand, CXCL12 (also known as SDF-1), is implicated in tumor growth, metastasis, and the mobilization of stem cells. Consequently, CXCR4 antagonists are designed to block this interaction, offering a targeted approach to disease intervention.

Several peptide-based compounds have emerged as potent CXCR4 antagonists. Among these, Peptide LY2510924 is a potent and selective CXCR4 antagonist that has shown significant promise. Clinical trials, such as the Phase I study reported by Galsky et al作者：H Guo·2017·被引用次数：39—Peptide LY2510924 is a potent and selective CXCR4 antagonistfor inhibiting renal cell carcinoma, lung, colon cancer and breast cancer that .... (2014), evaluated the safety and tolerability of CXCR4 inhibitor LY2510924. This study indicated that LY2510924 demonstrated CD34(+) cell mobilization at doses ≥2.A CXCR4 antagonist is a substance whichblocks the CXCR4 receptor and prevent its activation. Blocking the receptor stops the receptor's ligand, CXCL12, ...5 mg/day with a tolerable safety profile up to an MTD of 20 mg/day.Chemokine Receptor CXCR4 Antagonist - an overview Further research reinforces that LY2510924 is a potent and selective peptide antagonist of CXCR4 with demonstrated anti-tumor activities in multiple solid tumor xenograft models, as detailed by O'Hara et al.paclitaxel-conjugated CXCR4 peptide antagonist MB1707 (2020)EPI-X4, a CXCR4 antagonist inhibits tumor growth in ....

Another significant endogenous CXCR4 antagonist is EPI-X4作者：O Zirafi·2015·被引用次数：120—EPI-X4 forms an unusual lasso-like structure andantagonizes CXCL12-induced tumor cell migration, mobilizes stem cells, and suppresses inflammatory responses .... Discovered and characterized by Zirafi et alpaclitaxel-conjugated CXCR4 peptide antagonist MB1707. (2015), EPI-X4 exhibits an unusual lasso-like structure and functions by antagonizing CXCL12-induced tumor cell migration, mobilizing stem cells, and suppressing inflammatory responses. Recent work by Pohl et al. (2024) involved optimizing derivatives of EPI-X4, an endogenous peptide antagonist of CXCR4, demonstrating their potential in limiting tumor cell survival.

The development of novel CXCR4 peptide antagonist has been a key focus. For instance, Hassan et al作者：S Hassan·2011·被引用次数：168—CXCR4 peptide antagonistinhibits primary breast tumor growth, metastasis and enhances the efficacy of anti‐VEGF treatment or docetaxel in a .... (2011) demonstrated that a CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis, and enhances the efficacy of anti-VEGF treatment or docetaxel. This highlights the potential for designing a new CXCR4 antagonist to combat tumor spread. The same group further investigated this, reporting that increasing doses of a specific compound, CTCE-9908, alone slowed primary tumor growth with significant inhibition.In this study we developed a derivative of theCXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable ...

Beyond EPI-X4 and LY2510924, other peptide antagonists have been explored. The CXCR4 antagonist Plerixafor (AMD3100), also known as AMD3100, is a well-established small molecule antagonist used clinically for peripheral blood stem cell transplantation.作者：S Pawnikar·2022·被引用次数：8—The mechanism ofpeptideagonist binding inCXCR4remains unclear. Here, we have investigated this mechanism through all-atom simulations. However, its application is currently restricted to specific treatments due to potential side effects, as noted by Sokkar et al. (2021). Nevertheless, AMD3100, an antagonist of the chemokine receptor CXCR4, has been shown to mobilize stem cells and is approved for HSPC mobilization in combination therapies. It is also recognized for preventing leukemic cell accumulation in the bone marrow, thereby promoting treatment efficacy, according to Hitchinson et al.作者：J Pohl·2024·被引用次数：5—The inhibitors were optimized derivatives ofEPI-X4, an endogenous peptide antagonist of CXCR4. We observed that among all the candidates, EPI- ... (2018).Computational modeling and experimental validation of ...

Research continues to refine these peptide and small molecule CXCR4 antagonists. For example, Liu et al. (2018, 2019) focused on improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis, exploring modifications like acetylation with a PAMAM dendrimer作者：C Liu·2018·被引用次数：2—The E5peptide antagonisthas been designed and it was confirmed that it could specifically bind toCXCR4, which is a chemokine receptor involved in the .... Fang et alDiscovery and Characterization of an Endogenous CXCR4 .... (2017) investigated anti-tumor activity using nanomicelles encapsulating a CXCR4 antagonistCXCR4 antagonist. Furthermore, Wu et al. (2010) reported five independent crystal structures of CXCR4 bound to an antagonist small molecule IT1t and a cyclic peptide CVX15, providing crucial structural insights into receptor-antagonist interactions.

The mechanism by which these CXCR4 antagonists function is generally understood as a substance which blocks the CXCR4 receptor and prevents its activation. By blocking the receptor, they stop the interaction with its ligand, CXCL12, thereby inhibiting downstream signaling pathways. This fundamental action underpins their therapeutic potential. The general definition of a compound that inhibits the activity of the CXCR4 receptor applies to all these agents.CXCR4 antagonist More specifically, CXCR4 antagonists function by binding to the CXCR4 receptor on the surface of cells, thereby inhibiting the interaction between CXCR4 and its ligand, SDF-1.

The exploration of CXCR4 antagonists extends to specific variants and applications. For instance, a paclitaxel-conjugated CXCR4 peptide antagonist MB1707 has been developed, combining the anti-cancer drug paclitaxel with a CXCR4 inhibitor for potential antineoplastic activity. Moreover, research into CXCR4 antagonist 4 has focused on its properties, such as being a potent, orally active antagonist with reduced CYP 2D6 activity and improved permeability.

In summary, the development and study of CXCR4 peptide antagonists represent a significant advancement in targeted therapy作者：X Fang·2017·被引用次数：14—Therefore,designing a new CXCR4 antagonistto prevent tumor metastasis will be of great significance. Herein, a novel chemically synthesized peptide (E5) that .... From clinically approved drugs like AMD3100 to promising investigational agents such as LY2510924 and EPI-X4, these molecules offer a versatile approach to interfering with disease processes driven by the CXCR4 pathway, particularly in oncology. Continued research into the structure-activity relationships and novel formulations promises to further enhance their therapeutic efficacy and broaden their clinical impact. The ability to inhibit CXCL12-induced tumor cell migration and modulate stem cell behavior makes CXCR4 antagonists a critical area of ongoing scientific endeavorCXCR4 antagonist.